UCART-19

N/A

Report date: 2025/11/04 20:00:06

Base Information

Drug NameUCART-19

Drug Alias NameCD19CAR/RQR8+_TCRαβ–_T-cellsS-68587UCART-19UCART19S-95023

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsImmunologic cytotoxicity

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited KingdomFrance +[5]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCellectis Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAdir Sarl Institut De Recherches Internationales Servier

Active IndicationsN/A

Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A